Screener
Corcept Therapeutics CORT EV / EBITDA
EV / EBITDA at other companies
Other financials
Where this comes from
Calculated from Corcept Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
FAQ
- What is Corcept Therapeutics's EV / EBITDA?
- Corcept Therapeutics (CORT) reported EV / EBITDA of 1,093.2× in Q2 2026.
- How has Corcept Therapeutics's EV / EBITDA changed year-over-year?
- Corcept Therapeutics's EV / EBITDA increased by 1301.3% year-over-year, from 78× to 1,093.2×.
- What is the long-term trend for Corcept Therapeutics's EV / EBITDA?
- Over 5 years (2020 to 2025), Corcept Therapeutics's EV / EBITDA has grown at a 27.5% compound annual growth rate (CAGR), from 22.9× to 77.2×.
- What does EV / EBITDA mean?
- Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.
Ask your AI about Corcept Therapeutics's ev / ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude